Journal
IMMUNITY
Volume 48, Issue 3, Pages 453-473Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2018.03.009
Keywords
-
Categories
Funding
- Australian Research Council
- National Health and Medical Research Council
- Worldwide cancer research fund [16-1106]
- Cancer Council Victoria
- ARC Future Fellowships [FT140100278, FT160100074]
- ARC Laureate Fellowship
- NHMRC Senior Principal Research Fellowship
Ask authors/readers for more resources
Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and gamma delta T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available